Matthias E Meunier1,2, Yann Neuzillet3,4, Jean-François Dreyfus5, Marc Schneider6, Morgan Rouprêt7, Xavier Cathelineau8, Jean-Pierre Raynaud9, Thierry Lebret3,4, Henry Botto3. 1. Department of Urology, Université de Versailles-Saint-Quentin-en-Yvelines, Hôpital Foch, Service d'urologie40 rue Worth, 92150, Suresnes, France. matthias.meunier@yahoo.fr. 2. University of Versailles-Saint-Quentin-en-Yvelines, Versailles, France. matthias.meunier@yahoo.fr. 3. Department of Urology, Université de Versailles-Saint-Quentin-en-Yvelines, Hôpital Foch, Service d'urologie40 rue Worth, 92150, Suresnes, France. 4. University of Versailles-Saint-Quentin-en-Yvelines, Versailles, France. 5. Department of Clinical Research and Innovations, University of Versailles-Saint-Quentin-en-Yvelines, Versailles, France. 6. Department of Urology, Hôpital Louis Pasteur, Colmar, France. 7. Department of Urology, Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Sorbonne University, Paris, France. 8. Department of Urology, Institut Mutualiste Montsouris, Paris-Descartes University, Paris, France. 9. Sorbonne University, Paris, France.
Abstract
PURPOSE: PSA is known to be lowered in obese patients. There is a lack of data regarding patients with prostate cancer. Our objective was to prospectively assess the relationship PSA concentration, PSA mass and BMI in a cohort of patients with localized prostate cancer. METHODS: A prospective, multicenter cohort study was conducted including patients undergoing radical prostatectomy. Clinical and biological data were collected for each patient before surgery. RESULTS: A total of 1343 patients were analyzed. Mean age was 64.0 years. Mean weight was 82.2 kg and mean BMI was 26.8 kg/m2. Mean PSA concentration was 8.7 ng/mL and mean PSA mass 29.3 ng. On univariate analysis, an association was found between PSA mass and either BMI, weight and waist circumference. No association was found between PSA concentration and each weight parameters. On multivariate analysis, obesity was not an independent predictor of PSA concentration (p = 0.73). Independent predictors of PSA concentration were cardiovascular disease (negative association, p = 0.034), predominant Gleason 4 (positive association, p < 0.001) and pT3a (positive association, p < 0.001). BMI was an independent predictor of PSA mass (positive association, p = 0.009). PSA mass was negatively associated with TT (p = 0.015) and cardiovascular disease (p = 0.003), and positively associated with BT (p = 0.032), Gleason grade ≥ 4 + 3 (p < 0.001) and pT3a (p < 0.001). CONCLUSION: In this prospective study of patients with localized prostate cancer, higher BMI was associated with higher PSA mass but not with higher PSA concentration. Screening obese patients with a specific PSA method does not appear to be critical.
PURPOSE: PSA is known to be lowered in obese patients. There is a lack of data regarding patients with prostate cancer. Our objective was to prospectively assess the relationship PSA concentration, PSA mass and BMI in a cohort of patients with localized prostate cancer. METHODS: A prospective, multicenter cohort study was conducted including patients undergoing radical prostatectomy. Clinical and biological data were collected for each patient before surgery. RESULTS: A total of 1343 patients were analyzed. Mean age was 64.0 years. Mean weight was 82.2 kg and mean BMI was 26.8 kg/m2. Mean PSA concentration was 8.7 ng/mL and mean PSA mass 29.3 ng. On univariate analysis, an association was found between PSA mass and either BMI, weight and waist circumference. No association was found between PSA concentration and each weight parameters. On multivariate analysis, obesity was not an independent predictor of PSA concentration (p = 0.73). Independent predictors of PSA concentration were cardiovascular disease (negative association, p = 0.034), predominant Gleason 4 (positive association, p < 0.001) and pT3a (positive association, p < 0.001). BMI was an independent predictor of PSA mass (positive association, p = 0.009). PSA mass was negatively associated with TT (p = 0.015) and cardiovascular disease (p = 0.003), and positively associated with BT (p = 0.032), Gleason grade ≥ 4 + 3 (p < 0.001) and pT3a (p < 0.001). CONCLUSION: In this prospective study of patients with localized prostate cancer, higher BMI was associated with higher PSA mass but not with higher PSA concentration. Screening obese patients with a specific PSA method does not appear to be critical.
Authors: Stephanie E Bonn; Arvid Sjölander; Annika Tillander; Fredrik Wiklund; Henrik Grönberg; Katarina Bälter Journal: Int J Cancer Date: 2016-03-10 Impact factor: 7.396
Authors: Jonas Hugosson; Sigrid Carlsson; Gunnar Aus; Svante Bergdahl; Ali Khatami; Pär Lodding; Carl-Gustaf Pihl; Johan Stranne; Erik Holmberg; Hans Lilja Journal: Lancet Oncol Date: 2010-07-02 Impact factor: 41.316
Authors: Adel T Aref; Andrew D Vincent; Michael E O'Callaghan; Sean A Martin; Peter D Sutherland; Andrew J Hoy; Lisa M Butler; Gary A Wittert Journal: Endocr Relat Cancer Date: 2018-06-25 Impact factor: 5.678
Authors: Zachary Klaassen; Lauren E Howard; Daniel M Moreira; Gerald L Andriole; Martha K Terris; Stephen J Freedland Journal: Prostate Date: 2016-12-19 Impact factor: 4.104
Authors: Lindsey A Torre; Freddie Bray; Rebecca L Siegel; Jacques Ferlay; Joannie Lortet-Tieulent; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2015-02-04 Impact factor: 508.702
Authors: Nicolas Mottet; Joaquim Bellmunt; Michel Bolla; Erik Briers; Marcus G Cumberbatch; Maria De Santis; Nicola Fossati; Tobias Gross; Ann M Henry; Steven Joniau; Thomas B Lam; Malcolm D Mason; Vsevolod B Matveev; Paul C Moldovan; Roderick C N van den Bergh; Thomas Van den Broeck; Henk G van der Poel; Theo H van der Kwast; Olivier Rouvière; Ivo G Schoots; Thomas Wiegel; Philip Cornford Journal: Eur Urol Date: 2016-08-25 Impact factor: 20.096
Authors: Lionel L Bañez; Robert J Hamilton; Alan W Partin; Robin T Vollmer; Leon Sun; Carmen Rodriguez; Yiting Wang; Martha K Terris; William J Aronson; Joseph C Presti; Christopher J Kane; Christopher L Amling; Judd W Moul; Stephen J Freedland Journal: JAMA Date: 2007-11-21 Impact factor: 56.272
Authors: Martin G Sanda; Jeffrey A Cadeddu; Erin Kirkby; Ronald C Chen; Tony Crispino; Joann Fontanarosa; Stephen J Freedland; Kirsten Greene; Laurence H Klotz; Danil V Makarov; Joel B Nelson; George Rodrigues; Howard M Sandler; Mary Ellen Taplin; Jonathan R Treadwell Journal: J Urol Date: 2018-01-10 Impact factor: 7.450
Authors: Alex Tsodikov; Roman Gulati; Eveline A M Heijnsdijk; Paul F Pinsky; Sue M Moss; Sheng Qiu; Tiago M de Carvalho; Jonas Hugosson; Christine D Berg; Anssi Auvinen; Gerald L Andriole; Monique J Roobol; E David Crawford; Vera Nelen; Maciej Kwiatkowski; Marco Zappa; Marcos Luján; Arnauld Villers; Eric J Feuer; Harry J de Koning; Angela B Mariotto; Ruth Etzioni Journal: Ann Intern Med Date: 2017-09-05 Impact factor: 25.391